Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) – Analysts at Ascendiant Capital Markets boosted their Q1 2027 earnings per share estimates for shares of Alzamend Neuro in a research note issued to investors on Tuesday, August 18th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings per share of ($0.56) for the quarter, up from their prior estimate of ($0.67). The consensus estimate for Alzamend Neuro’s current full-year earnings is ($2.60) per share. Ascendiant Capital Markets also issued estimates for Alzamend Neuro’s Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($1.05) EPS.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last released its earnings results on Wednesday, July 22nd. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07).
View Our Latest Stock Report on ALZN
Alzamend Neuro Stock Performance
NASDAQ:ALZN opened at $1.55 on Tuesday. Alzamend Neuro has a one year low of $0.84 and a one year high of $2.68. The business’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.38. The stock has a market cap of $7.42 million, a price-to-earnings ratio of -0.53 and a beta of 0.16.
Institutional Trading of Alzamend Neuro
An institutional investor recently raised its stake in Alzamend Neuro stock. DRW Securities LLC boosted its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 27.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the period. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 as of its most recent SEC filing. 49.61% of the stock is owned by institutional investors and hedge funds.
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Alzamend Neuro
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
